Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Unicycive Therapeutics, Inc. UNCY

Healthcare  —  Biotechnology
4.70 (0.11) (2.29%) as of 25 Sep
Market cap
$134.0M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Unicycive Therapeutics, Inc. (UNCY) Business Profile

Updated before January 2025

Company Overview

Unicycive Therapeutics, Inc. (UNCY) is a clinical-stage biotechnology company dedicated to developing innovative treatments for kidney diseases and other critical medical conditions. Founded in 2016, the company is headquartered in Los Altos, California. Unicycive was established with the mission of addressing significant unmet medical needs in nephrology and other therapeutic areas. The company is led by a team of seasoned professionals with extensive experience in biotechnology, pharmaceuticals, and healthcare. Key leadership includes Shalabh Gupta, M.D., who serves as the Chief Executive Officer and President, bringing a wealth of expertise in drug development and commercialization.

Core Business Segments

Unicycive Therapeutics focuses on developing novel therapies for kidney diseases and related conditions. The company’s core business segments include:

1. Therapeutics for Kidney Diseases

  • Renazorb: A proprietary phosphate binder designed to treat hyperphosphatemia in patients with chronic kidney disease (CKD). Renazorb is formulated to reduce pill burden and improve patient compliance compared to existing treatments.
  • UNI-494: A novel drug candidate targeting acute kidney injury (AKI). UNI-494 is designed to address mitochondrial dysfunction, a key factor in the progression of AKI.

2. Research and Development (R&D)

Unicycive invests heavily in R&D to discover and develop new therapies. The company leverages cutting-edge science and technology to create innovative solutions for kidney-related conditions and other unmet medical needs.

Business Model

Unicycive Therapeutics operates on a business model centered around innovation, strategic partnerships, and commercialization. The company’s approach includes:

  • Product Development: Unicycive focuses on advancing its pipeline of drug candidates through clinical trials and regulatory approvals.
  • Strategic Collaborations: The company partners with academic institutions, research organizations, and other biotech firms to accelerate drug development and expand its capabilities.
  • Revenue Generation: Unicycive plans to generate revenue through the commercialization of its products, licensing agreements, and potential partnerships with larger pharmaceutical companies.

Strategic Direction

Unicycive Therapeutics has a clear strategic vision aimed at achieving long-term growth and sustainability. Key elements of the company’s strategic direction include:

  • Pipeline Expansion: Unicycive is committed to advancing its existing drug candidates, such as Renazorb and UNI-494, while exploring new therapeutic areas.
  • Global Market Penetration: The company aims to expand its presence in international markets by securing regulatory approvals and establishing distribution networks.
  • Sustainability Goals: Unicycive is focused on developing cost-effective therapies that improve patient outcomes and reduce the overall burden on healthcare systems.
  • Innovation: The company continues to invest in R&D to discover breakthrough therapies and maintain its competitive edge.

Competitive Landscape

Unicycive Therapeutics operates in a highly competitive biotechnology and pharmaceutical industry. Key competitors include:

  • Akebia Therapeutics: Focused on developing treatments for kidney diseases, including anemia associated with CKD.
  • Amgen: A global leader in biotechnology with a strong presence in nephrology.
  • Keryx Biopharmaceuticals: Specializes in treatments for hyperphosphatemia and other kidney-related conditions.
  • Vifor Pharma: A leading provider of therapies for iron deficiency and kidney diseases.

Unicycive differentiates itself through its innovative drug candidates, patient-centric approach, and commitment to addressing unmet medical needs.

Risk Factors

Like any biotechnology company, Unicycive Therapeutics faces several risks, including:

  • Regulatory Challenges: The company’s drug candidates must undergo rigorous clinical trials and obtain regulatory approvals, which can be time-consuming and costly.
  • Market Dependence: Unicycive’s success depends on the commercial viability of its products, particularly Renazorb and UNI-494.
  • Supply Chain Disruptions: The company relies on third-party manufacturers and suppliers, making it vulnerable to supply chain issues.
  • Competition: The biotechnology industry is highly competitive, with numerous companies vying for market share in the nephrology space.
  • Financial Risks: As a clinical-stage company, Unicycive may face challenges in securing funding to support its operations and R&D activities.

Recent Developments

Unicycive Therapeutics has made significant progress in advancing its pipeline and corporate strategy. Recent developments include:

  • Clinical Trials: The company has initiated clinical trials for Renazorb and UNI-494, demonstrating its commitment to bringing these therapies to market.
  • Regulatory Milestones: Unicycive has achieved key regulatory milestones, including Investigational New Drug (IND) approvals for its drug candidates.
  • Partnerships: The company has entered into strategic collaborations with leading research institutions to accelerate drug development.
  • Global Developments: Unicycive is actively pursuing regulatory approvals in international markets, positioning itself for global expansion.

Investment Considerations

Investors considering Unicycive Therapeutics should weigh the following factors:

Strengths

  • Innovative Pipeline: The company’s focus on novel therapies for kidney diseases positions it as a leader in the nephrology space.
  • Experienced Leadership: Unicycive’s management team brings extensive expertise in drug development and commercialization.
  • Market Potential: The global market for kidney disease treatments is growing, offering significant opportunities for Unicycive’s products.

Risks

  • Clinical and Regulatory Risks: The success of Unicycive’s drug candidates depends on the outcomes of clinical trials and regulatory approvals.
  • Financial Uncertainty: As a clinical-stage company, Unicycive may face challenges in securing funding to support its operations.
  • Competitive Pressure: The company operates in a highly competitive industry, with established players and emerging startups.

Conclusion

Unicycive Therapeutics, Inc. is a promising biotechnology company with a strong focus on developing innovative therapies for kidney diseases. With a robust pipeline, experienced leadership, and a commitment to addressing unmet medical needs, Unicycive is well-positioned for growth. However, investors should carefully consider the risks associated with clinical-stage companies and the competitive landscape. As Unicycive advances its drug candidates and expands its global presence, it has the potential to make a significant impact in the biotechnology industry.